Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

被引：0
|
作者：
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy Vladimirovich
Merle, Philippe
Kaseb, Ahmed Omar
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Ding, Beiying
Zhu, Andrew X.
Cheng, Ann-Lii
机构：
[1] UCLA, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA
[2] Jinling Hosp, Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China
[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[4] Univ Med Ctr, Mainz, Germany
[5] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[8] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
[9] NN Blokhin Minist Hlth, Russian Oncol Res Ctr, Moscow, Russia
[10] Hosp La Croix Rousse, Lyon, France
[11] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX 77030 USA
[12] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[13] Beckman Res Inst, Duarte, CA USA
[14] Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol, Tainan, Taiwan
[15] Genentech Inc, San Francisco, CA 94080 USA
[16] Roche Prod Dev, Shanghai, Peoples R China
[17] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[18] Natl Taiwan Univ Hosp, Taipei, Taiwan
[19] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4596
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Atezolizumab (ATEZO) plus Bevacizumab ( BEV) vs Sorafenib (SOR) in Patients (PTS) with Unresectable Hepatocellular Carcinoma (HCC): Phase 3 Results from Imbrave150
    Galle, Peter R.
    Cheng, Ann-Lll
    Qin, Shukui
    Ikeda, Masafumi
    Ducreux, Michel
    Zhu, Andrew
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Verret, Wendy
    Xu, Derek
    Hernandez, Sairy
    Liu, Juan
    Shao, Hui
    Mulla, Sohail
    Lim, Hy
    Finn, Richard
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 220 - 220
  • [2] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
  • [3] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study
    Ducreux, Michel
    Zhu, Andrew
    Qin, Shukui
    Ikeda, Masafumi
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Verret, Wendy
    Xu, Zhen
    Hernandez, Sairy
    Liu, Juan
    Shao, Hui
    Huang, Chen
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    JOURNAL OF HEPATOLOGY, 2020, 73 : S121 - S121
  • [5] IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDY
    Zhu, Andrew X.
    Finn, Richard
    Ducreux, Michel
    Hu, Youyou
    Sommer, Nicolas
    Verret, Wendy
    Kulik, Laura M.
    Galle, Peter R.
    HEPATOLOGY, 2021, 74 : 646A - 647A
  • [6] IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li Daneng
    Verret, Wendy
    Shao Hui
    Liu Juan
    Li Lindong
    Zhu, Andrew X.
    Chen, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
    Ducreux, Michel
    Zhu, Andrew X.
    Cheng, Ann-Lii
    Galle, Peter R.
    Ikeda, Masafumi
    Nicholas, Alan
    Verret, Wendy
    Li, Lindong
    Gaillard, Vincent E.
    Lencioni, Riccardo
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [10] HEPATIC EVENTS AND VIRAL KINETICS IN PATIENTS (PTS) WITH HEPATITIS B/C VIRUS (HBV/HCV)-RELATED, UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) OR SORAFENIB (SOR) IN IMbrave150
    Hsu, Chiun
    Ducreux, Michel
    Zhu, Andrew X.
    Qin, Shukui
    Ikeda, Masafumi
    Kim, Tae-You
    Galle, Peter R.
    Finn, Richard
    Chen, Ethan
    Shao, Hui
    Stanzel, Sven Franz
    Xu, Derek-Zhen
    Cheng, Ann-Lii
    HEPATOLOGY, 2020, 72 : 779A - 780A
12345